U.S. Basic Materials Stock News

MSCI Inc. has reported its second-quarter 2026 results, with sales rising to US$867 million from US$772.7 million a year earlier and net income increasing to US$342 million from US$303.7 million, alongside higher earnings per share. Alongside these results, MSCI highlighted expanding AI-led tools, new product launches, and a growing private-markets platform, signaling a deeper push into data and analytics for less transparent asset classes. Next, we’ll examine how MSCI’s strong earnings and...

Sprouts Farmers Market stock has delivered a strong 202.5% return over the past 5 years, yet its current checks still point to shares screening as undervalued on several key measures. Over 5 years, Sprouts Farmers Market has returned 202.5%, which puts the recent pullback into context as a longer term compounding story rather than a short term trade. For valuation, the main support can come from the company sustaining healthy cash generation and margins, while a key risk is any pressure on...

Recent performance context for Dillard's stock Dillard's (DDS) has seen mixed share performance recently, with the stock up over the past day and month, but down over the past 3 months and year to date, prompting closer attention from investors. See our latest analysis for Dillard's. At the current share price of $568.27, Dillard's has posted a 7.75% 7 day share price return and a 2.42% 30 day share price return, but the 90 day share price return is down 6.69% and the year to date share price...

We feel now is a pretty good time to analyse BioHarvest Sciences Inc.'s ( NASDAQ:BHST ) business as it appears the...

Bristol-Myers Squibb (BMY) is back in focus after the FDA accepted its New Drug Application for mezigdomide in relapsed or refractory multiple myeloma, alongside a new AI collaboration with Nvidia for drug discovery. See our latest analysis for Bristol-Myers Squibb. The recent FDA filing for mezigdomide and the AI expansion with Nvidia come as Bristol-Myers Squibb’s share price has gained momentum, with a 12.83% 1 month share price return and 13.97% year to date, while the 1 year total...

Bank of America recently added Keurig Dr Pepper (KDP) to its U.S. 1 List, drawing fresh attention to the beverage company’s stock and its mix of coffee, soft drinks, and other consumer drinks. See our latest analysis for Keurig Dr Pepper. The recent addition of Keurig Dr Pepper to Bank of America’s U.S. 1 List comes after a period where the stock’s 90 day share price return rose 13.83%, while its 1 year total shareholder return declined 7.56%. This combination suggests improving short term...

Bitdeer Technologies Group (NasdaqCM:BTDR) recently reported unaudited June 2026 operating metrics that highlighted record Bitcoin production, a larger managed hash rate base, and progress on AI infrastructure and hardware manufacturing projects across multiple regions. See our latest analysis for Bitdeer Technologies Group. The June update and recent AI and manufacturing projects come after a mixed share price run for Bitdeer Technologies Group, with a 1-day share price return of 9.76%, a...

We'd be surprised if The Greenbrier Companies, Inc. ( NYSE:GBX ) shareholders haven't noticed that the Senior VP...

The investors in Frequency Electronics, Inc. 's ( NASDAQ:FEIM ) will be rubbing their hands together with glee today...

In July 2026, Summit Therapeutics Inc. announced it had signed an agreement with Toronto-based Biossil Inc. to sell ridinilazole, its Phase III investigational precision antibiotic, for US$500,000 upfront plus up to US$104.5 million in potential regulatory and commercial milestones and tiered royalties on future net sales. This transaction effectively monetizes a non-core antibiotic asset, potentially allowing Summit to redirect capital and management focus toward its oncology programs...

Morgan Stanley recently raised concerns about Vertex’s ability to reach its end-market potential amid a transition period and rising artificial intelligence pressures in tax compliance technology. The commentary highlights that AI is emerging not just as a tool but also as a competitive threat that could reshape the tax automation landscape for Vertex. We’ll now examine how Morgan Stanley’s AI-related growth concerns may influence Vertex’s existing investment narrative around...

PPL (PPL) is drawing investor attention after outlining a planned US$23 billion investment program through 2029, supported by disciplined cost management and closely tied to its current earnings guidance. See our latest analysis for PPL. Despite the fresh US$23 billion investment plan and grid upgrade story, PPL's recent momentum has softened, with the share price down over the past quarter. However, the 3 year total shareholder return of 40.04% and 5 year total shareholder return of 47.30%...

Progyny stock has climbed 40.3% over the past year, and investors now face a clear split between valuation signals, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to around 50% upside while market multiples suggest the shares screen as expensive. Over the last 12 months, Progyny has delivered a 40.3% return, which puts more pressure on today’s buyers to judge whether that performance already reflects the good news in the price. Recent analyst upgrades tied to stronger...

Boston Scientific stock is coming off a difficult stretch, with the share price down 58.1% over the past year, yet the broader valuation checks still lean toward the stock looking inexpensive relative to its fundamentals. That gap between weak recent returns and a stronger value profile is what current and prospective holders are trying to make sense of. Over the past 1 year, Boston Scientific has declined 58.1%, which puts recent sentiment under pressure even as longer term holders reassess...

Recent Trading Context For CRISPR Therapeutics Stock CRISPR Therapeutics (NasdaqGM:CRSP) has been trading with mixed short term moves, rising about 2.5% over the past day while declining around 4.6% over the past week and 11% over the past month. See our latest analysis for CRISPR Therapeutics. At a share price of $48.15, CRISPR Therapeutics has seen short term share price pressure, with the 30 day share price return down 10.98% and the year to date share price return down 10.45%, alongside a...

CME Group stock has given investors a solid 5 year return, yet current checks suggest it is not obviously cheap, with the Excess Returns intrinsic value estimate sitting close to the market price while earnings based multiples point to a premium. CME Group has returned about 37% over the past 5 years, which is respectable but not a runaway result that clearly justifies paying any price. New product launches such as Treasury Link and expanded agriculture contracts can support long term fee...

Sunoco (NYSE:SUN) has closed a $275 million shelf registration tied to the issuance of 10,000,000 common units. The offering is connected to an Employee Stock Ownership Plan and affects how equity is allocated to employees. The closure finalizes a capital markets move that may influence Sunoco's capital structure and ownership mix. For investors tracking Sunoco, the completion of this ESOP related shelf registration comes at a time when the stock trades around $74.99 and has produced strong...

Silicon Motion Technology stock has delivered a very strong three year return, yet the broader valuation checks lean expensive, which raises questions about how much optimism is already reflected in the current price of US$278.17. Over the last three years, Silicon Motion Technology has returned about 4.8x an initial investment, which sets a high bar for what needs to go right from here to justify that performance. Expansion into areas such as AI infrastructure and automotive storage can...

Definium Therapeutics stock has delivered a very large 3 year gain, yet the valuation checks and current market pricing now point to a more cautious picture, with the shares screening as expensive on traditional multiples. Over the past 3 years, Definium Therapeutics has returned about 9.2x, which sets a high bar for any further upside to be justified by fundamentals. Positive Phase 3 data for DT120 in depression and the recent US$805m capital raise can support expectations for future...

Allient stock has returned about 180% over the past five years. Yet at around US$89.97 per share, both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiple checks currently point to the shares trading at a premium rather than as an obvious bargain. Over five years, a roughly 180% share price gain suggests early investors have already seen strong compounding. This can limit the margin of safety for anyone considering the stock today. Future cash flow growth and the...

AppLovin (APP) is back in focus after a disputed short-seller report and rising competition in AI-powered advertising, with management emphasizing profit margins, stock buybacks, and its expanding monetization platform to influence sentiment. See our latest analysis for AppLovin. The recent short seller dispute and rising AI ad competition have played into AppLovin’s sharp share price reset, with the stock down 30.67% on a year to date share price return and 8.73% over 30 days, even as the 1...

In recent days, United Parcel Service (UPS) has faced increased scrutiny ahead of its now-past Q2 2026 earnings release, as analysts weighed expectations for higher revenue and modest earnings growth against evolving parcel pricing trends and shifting fuel surcharges. At the same time, rising delivery costs and Amazon Shipping’s more aggressive pricing have highlighted how quickly competition can reshape UPS’s parcel economics and bargaining power with customers. We’ll now examine how...

Why Universal Health Services stock is in focus Universal Health Services (UHS) is back on investors radar after two recent corporate moves: a new delayed draw term loan facility of up to $700 million and a reaffirmed quarterly cash dividend. See our latest analysis for Universal Health Services. At a share price of $149.91, Universal Health Services has seen its 7 day share price return rise 3.94% and its 30 day share price return rise 6.19%. However, the 90 day share price return has fallen...

Norfolk Southern recently faced two significant developments: analyst expectations for Q2 2026 earnings and revenue, and new lawsuits alleging long-term worker exposure to toxic substances and safety violations under the Federal Employers' Liability Act. Together, shifting earnings estimates and mounting legal claims highlight how operational performance and potential liability risks are becoming increasingly intertwined for the railroad operator. Next, we'll examine how renewed Q2 earnings...